

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7856926

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TECPHARMA LICENSING AG	12/15/2022
RECEIVING PARTY DATA	
Name:	PFIZER INC.
Street Address:	235 EAST 42ND STREET
Internal Address:	ATTN: LEGAL PATENT DEPARTMENT, CHIEF IP COUNSEL
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10017
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	7771399
Patent Number:	8075534
Patent Number:	7811263
Patent Number:	8721601
Patent Number:	7867202
Application Number:	11550998
Application Number:	12839987
Application Number:	11439389
Application Number:	11943818
Application Number:	11943333
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	pfizerpatentdocketing@pfizer.com
Correspondent Name:	PFIZER INC.
Address Line 1:	235 EAST 42ND STREET
Address Line 2:	ATTN: LEGAL PATENT DEPARTMENT, CHIEF IP COUNSEL
Address Line 4:	NEW YORK, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	PC35581,35583,35584,35586
NAME OF SUBMITTER:	MARGARET ABBOTT
SIGNATURE:	/Margaret Abbott/
DATE SIGNED:	03/21/2023
Total Attachments: 2 source=TecPharma Assignment#page1.tif source=TecPharma Assignment#page2.tif	

ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS is entered into with effect on December 15, 2022 by and between:

TecPharma Licensing AG, Brunnmattstrasse 6, CH-3400 Burgdorf, hereinafter referred to as "TPL"

and

Pfizer Inc., 235 East, 42nd Street, New York, New York 10017, United States of America, hereinafter referred to as "Pfizer"

TPL and Pfizer are each referred to as a "Party" and collectively as the "Parties".

WHEREAS, TPL is the owner of the following registered and granted patent rights:

Technique/Title	Country	Patent no.	Priority date	Assignor
Locking Dose Selection / Injection device comprising a dosing unit with multiple anti- twist protection (App. F #4)	DE / FR	EP1742688 B1	23.04.2004	TecPharma Licensing AG
	US	US7771399 B2		
		US8075534 B2		
Mechanical Design Display / Administering device comprising a display drum (App. F #6)	DE	DE102005023854 B4	24.05.2005	TecPharma Licensing AG
	US	US7811263 B2		
Dosing Stop / Dosing device for an injection device (App. F #7)	DE / FR	EP1888148 B1	24.05.2005	TecPharma Licensing AG
	US	US8721601 B2		
Blocking Last Dose / Dosiervorrichtung für eine Injektionsvorrichtung (App. F #8)	DE	DE102005023823 B4 (granted 17.11.2022)	24.05.2005	TecPharma Licensing AG
One-way Locking Dosing Mechanism of Stroke Sleeve / Threaded rod and dosing device for an injection device (App. F #9)	DE / FR	EP1888149 B1	24.05.2005	TecPharma Licensing AG
	US	US7867202 B2		
	DE / FR	EP2065065 B2		

hereinafter "the Patents" (5 US , 2 DE national , 4 FR validated, 4 DE validated Patents, totally 15 IPRs)

WHEREAS, Pfizer desires to acquire the ownership of the Patents, and TPL in turn, desires to sell to Pfizer the Patents.

NOW, THEREFORE, the parties hereby enter into the following agreement:

1. OBJECT

TPL hereby sells, assigns, transfers and conveys to Pfizer and Pfizer hereby acquires and purchases all rights, titles and interests TPL has in, and to the Patents. It becomes descretion of TPL to let lapse all IPR other than the Patents claiming the same priority as the Patents.

2. SALE / PURCHASE / COMMERCIAL TERMS

The present transfer for the Patents is made and accepted for a consideration of the sum of SIXTEEN THOUSAND EIGHT HUNDRED AND THIRTY EUROS. Pfizer shall make a one-time payment (EUR 16'830.-) within forty-five (45) days after the Effective Date to TPL.

Payment is to be made to:

Bank: Credit Suisse (Schweiz) AG
Account no.: 899759-22
IBAN: CH09 0483 5089 9759 2200 0
SWIFT: CRESCHZZ80A

3. RECORDING OF THE TRANSFER

TPL, the assignor, listed as the registered holder of the Patents hereby authorizes the respective Intellectual Property Offices in Europe, France, Germany and the United States of America to record the transfer of the Patents to Pfizer as assignee of TPL's entire right, title and interest therein, in accordance with this Assignment. Pfizer will take care of the recording of the transfer of the Patents, at its own expenses, and TPL shall execute without delay any further assignment documents as needed.

4. ENTIRE AGREEMENT

This agreement sets forth the entire agreement and understanding of the Parties with respect to the subject matter hereof, and supersedes all prior discussions, agreements and writings relating thereto. This agreement may not be altered, amended or modified in any way except in writing signed by both Parties.

5. GOVERNING LAW AND JURISDICTION


This Agreement and any disputes arising out of or relating to it shall be subject to the exclusive jurisdiction of the courts of Berne, Switzerland.

This Agreement may be executed in counterparts, each of which is an original, and all of which, taken together, shall be one instrument.


IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be executed as of the Effective Date.

Burgdorf, 15.11.22

TecPharma Licensing AG



Dr. Beat Maurer
Attorney-at-Law



Adrian Eich
Head of Patent and Trademark Dept.

Pfizer Inc.



Lisa Samuels
Assistant General Counsel